Houlahan and House Colleagues Introduce the Biomanufacturing Excellence Act

Photo credit: Mikhail Nilov (Pexels)

Washington. D.C. , November 18, 2025 | Errin S. Cecil-Smith (202-253-4220)

Today, U.S. Representative Chrissy Houlahan and House colleagues Jim Baird (R-Ind.), David Rouzer (R-N.C.), and Deborah Ross (D-N.C.)  introduced the Biomanufacturing Excellence Act, which would promote U.S. leadership in biotechnology and strengthen domestic biopharmaceutical manufacturing. Companion legislation is being led in the U.S. Senate by Senators Chris Coons (D-Del.) and Ted Budd (R-N.C.)

Biotechnology will shape how the United States defends itself, secures its food supply, and cures life-threatening diseases. The National Security Commission on Emerging Biotechnology (NSCEB) warned that without rapid and significant investment, the U.S. will fall behind its global competitors, specifically China. China’s share of global pharmaceutical output has surged from about 5% in 2002 to nearly 25% in 2019. This legislation reinvests in domestic biopharmaceutical manufacturing, reducing dependence on unreliable foreign supply chains, expanding access to cutting-edge medicines, and supporting high-quality American jobs. 

The Biomanufacturing Excellence Act would establish a public-private center dedicated to advancing biopharmaceutical manufacturing – a key recommendation from the National Security Commission on Emerging Biotechnology (NSCEB) report.

Read More